Rocket Pharmaceuticals (RCKT) announced that it has received clearance from the FDA for the company’s investigational new drug application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy, a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.